参考文献:
1、Reck M, Rodríguez‑Abreu D, et al, for the KEYNOTE-024 investigators, Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med.2016;375(19):1823–1833.
2、Gandhi L, Rodríguez-Abreu D, et al, for the KEYNOTE-189 Investigators, Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
3、https://www./hcp/nsclc/first-line-combination-therapy/#subgroups
4、Cancer incidence and mortality in China, 2014. Chin J Cancer Res 2018;30(1)。http://zhzlzz./CN112152201801/1020789.jhtml 2014年中国分地区恶性肿瘤发病和死亡分析,中华肿瘤杂志,2018年第27卷第1期
5、http://abstracts./214/AbstView_214_218423.html
6、http://abstracts./214/AbstView_214_228023.html